Dong-A ST Co., Ltd. (170900.KS)
KRW 47300.0
(-1.77%)
KRW 47300.0
(-1.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 11.12 Billion KRW | -17.93% |
| 2022 | 13.55 Billion KRW | 5.74% |
| 2021 | 12.81 Billion KRW | -52.71% |
| 2020 | 27.1 Billion KRW | -61.78% |
| 2019 | 70.91 Billion KRW | 785.44% |
| 2018 | 8 Billion KRW | 248.43% |
| 2017 | -5.39 Billion KRW | -150.77% |
| 2016 | 10.62 Billion KRW | -78.11% |
| 2015 | 48.56 Billion KRW | 29.8% |
| 2014 | 37.41 Billion KRW | 156.93% |
| 2013 | -65.71 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.61 Billion KRW | -25.54% |
| 2024 Q2 | 328.33 Million KRW | 103.81% |
| 2023 Q2 | 1.82 Billion KRW | -76.27% |
| 2023 Q3 | 8.46 Billion KRW | 363.74% |
| 2023 Q1 | 7.69 Billion KRW | 157.09% |
| 2023 Q4 | -6.85 Billion KRW | -181.04% |
| 2023 FY | 11.12 Billion KRW | -17.93% |
| 2022 Q4 | -13.47 Billion KRW | -162.7% |
| 2022 Q2 | 3.01 Billion KRW | 73.71% |
| 2022 Q1 | 1.73 Billion KRW | 130.19% |
| 2022 FY | 13.55 Billion KRW | 5.74% |
| 2022 Q3 | 21.48 Billion KRW | 611.88% |
| 2021 Q1 | 762.09 Million KRW | 105.24% |
| 2021 Q3 | 11.54 Billion KRW | 84.23% |
| 2021 Q4 | -5.75 Billion KRW | -149.86% |
| 2021 FY | 12.81 Billion KRW | -52.71% |
| 2021 Q2 | 6.26 Billion KRW | 722.18% |
| 2020 Q3 | 4.15 Billion KRW | 146.46% |
| 2020 FY | 27.1 Billion KRW | -61.78% |
| 2020 Q2 | -8.93 Billion KRW | -119.25% |
| 2020 Q1 | 46.43 Billion KRW | 102.0% |
| 2020 Q4 | -14.54 Billion KRW | -450.15% |
| 2019 FY | 70.91 Billion KRW | 785.44% |
| 2019 Q4 | 22.98 Billion KRW | 16.33% |
| 2019 Q3 | 19.75 Billion KRW | 146.85% |
| 2019 Q2 | 8 Billion KRW | -60.3% |
| 2019 Q1 | 20.16 Billion KRW | 175.75% |
| 2018 Q2 | 21.6 Billion KRW | 186.12% |
| 2018 FY | 8 Billion KRW | 248.43% |
| 2018 Q3 | 5.46 Billion KRW | -74.71% |
| 2018 Q4 | -26.61 Billion KRW | -587.11% |
| 2018 Q1 | 7.55 Billion KRW | 178.34% |
| 2017 Q2 | 4.58 Billion KRW | 140.16% |
| 2017 Q1 | -11.41 Billion KRW | -221.9% |
| 2017 Q3 | 11.07 Billion KRW | 141.62% |
| 2017 FY | -5.39 Billion KRW | -150.77% |
| 2017 Q4 | -9.64 Billion KRW | -187.03% |
| 2016 Q4 | 9.36 Billion KRW | 2509.83% |
| 2016 FY | 10.62 Billion KRW | -78.11% |
| 2016 Q1 | 4.67 Billion KRW | -71.14% |
| 2016 Q2 | -3.02 Billion KRW | -164.71% |
| 2016 Q3 | -388.65 Million KRW | 87.16% |
| 2015 FY | 48.56 Billion KRW | 29.8% |
| 2015 Q3 | 11.17 Billion KRW | -9.96% |
| 2015 Q2 | 12.4 Billion KRW | 41.45% |
| 2015 Q1 | 8.77 Billion KRW | -23.73% |
| 2015 Q4 | 16.21 Billion KRW | 45.15% |
| 2014 Q1 | 8.39 Billion KRW | -27.34% |
| 2014 Q2 | 6.71 Billion KRW | -19.94% |
| 2014 Q3 | 10.8 Billion KRW | 60.75% |
| 2014 Q4 | 11.5 Billion KRW | 6.48% |
| 2014 FY | 37.41 Billion KRW | 156.93% |
| 2013 Q2 | 4.1 Billion KRW | 104.64% |
| 2013 FY | -65.71 Billion KRW | 0.0% |
| 2013 Q1 | -88.33 Billion KRW | 0.0% |
| 2013 Q3 | 6.96 Billion KRW | 69.92% |
| 2013 Q4 | 11.55 Billion KRW | 65.73% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 254.89% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 80.82% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 543.76% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 114.092% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 118.666% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 50.197% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 232.171% |
| Yuhan Corporation | 93.5 Billion KRW | 88.106% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 144.827% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -217.005% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 636.304% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 345.809% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 41.169% |
| CKD Bio Corp. | -24.19 Billion KRW | 145.975% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 254.89% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -210.391% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 109.404% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 69.944% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 119.402% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -81.687% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 386.991% |
| HANDOK Inc. | -28.79 Billion KRW | 138.623% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 254.89% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 69.911% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 90.025% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 69.944% |
| Yuhan Corporation | 93.5 Billion KRW | 88.106% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 168.447% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 92.394% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 94.766% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -81.763% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 69.944% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 76.339% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 153.114% |
| JW Holdings Corporation | 19.02 Billion KRW | 41.542% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -568.602% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -122.238% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 119.402% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 53.495% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 76.954% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 62.644% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 59.464% |
| Boryung Corporation | 40.2 Billion KRW | 72.334% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 135.501% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 543.76% |
| JW Lifescience Corporation | 28.14 Billion KRW | 60.48% |